Vaxcyte, Inc. (NASDAQ:PCVX) Shares Sold by Braidwell LP

Braidwell LP reduced its position in Vaxcyte, Inc. (NASDAQ:PCVX - Free Report) by 25.3% during the 4th quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The firm owned 222,424 shares of the company's stock after selling 75,144 shares during the quarter. Braidwell LP owned about 0.18% of Vaxcyte worth $18,208,000 at the end of the most recent quarter.

A number of other hedge funds also recently made changes to their positions in PCVX. Whipplewood Advisors LLC bought a new position in Vaxcyte during the fourth quarter worth $28,000. Smartleaf Asset Management LLC raised its position in Vaxcyte by 188.4% in the fourth quarter. Smartleaf Asset Management LLC now owns 398 shares of the company's stock worth $33,000 after acquiring an additional 260 shares during the period. National Bank of Canada FI purchased a new stake in Vaxcyte during the fourth quarter valued at about $41,000. Blue Trust Inc. raised its stake in shares of Vaxcyte by 100.0% during the 4th quarter. Blue Trust Inc. now owns 742 shares of the company's stock valued at $61,000 after purchasing an additional 371 shares during the period. Finally, Assetmark Inc. grew its position in shares of Vaxcyte by 77,500.0% during the 4th quarter. Assetmark Inc. now owns 776 shares of the company's stock valued at $64,000 after purchasing an additional 775 shares in the last quarter. 96.78% of the stock is currently owned by institutional investors and hedge funds.

Vaxcyte Trading Down 0.9 %

NASDAQ:PCVX traded down $0.29 during midday trading on Friday, reaching $31.16. The company had a trading volume of 2,030,375 shares, compared to its average volume of 1,309,427. Vaxcyte, Inc. has a 12-month low of $27.66 and a 12-month high of $121.06. The stock's fifty day simple moving average is $46.66 and its 200-day simple moving average is $74.46. The firm has a market capitalization of $4.02 billion, a price-to-earnings ratio of -6.77 and a beta of 1.27.

Vaxcyte (NASDAQ:PCVX - Get Free Report) last issued its quarterly earnings results on Wednesday, May 14th. The company reported ($1.04) earnings per share (EPS) for the quarter, missing the consensus estimate of ($1.02) by ($0.02). During the same quarter in the previous year, the business posted ($0.85) earnings per share. As a group, sell-side analysts expect that Vaxcyte, Inc. will post -4.21 EPS for the current year.

Insiders Place Their Bets

In other Vaxcyte news, COO Jim Wassil sold 8,000 shares of Vaxcyte stock in a transaction that occurred on Monday, March 3rd. The shares were sold at an average price of $73.27, for a total transaction of $586,160.00. Following the transaction, the chief operating officer now directly owns 154,931 shares of the company's stock, valued at $11,351,794.37. The trade was a 4.91 % decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which is accessible through this hyperlink. 3.10% of the stock is currently owned by company insiders.

Analyst Upgrades and Downgrades

PCVX has been the subject of a number of research reports. Bank of America cut their price objective on shares of Vaxcyte from $157.00 to $137.00 and set a "buy" rating for the company in a research note on Tuesday, April 1st. The Goldman Sachs Group lowered their price target on Vaxcyte from $138.00 to $100.00 and set a "buy" rating on the stock in a report on Tuesday, April 1st. Evercore ISI raised shares of Vaxcyte to a "strong-buy" rating in a research note on Monday, March 31st. Needham & Company LLC restated a "buy" rating and set a $90.00 price target on shares of Vaxcyte in a report on Tuesday, April 8th. Finally, Guggenheim reaffirmed a "buy" rating and set a $160.00 price target on shares of Vaxcyte in a research note on Wednesday, March 12th. Nine investment analysts have rated the stock with a buy rating and one has issued a strong buy rating to the stock. According to data from MarketBeat.com, the stock currently has an average rating of "Buy" and a consensus price target of $136.50.

Vaxcyte Company Profile

Vaxcyte, Inc, a clinical-stage biotechnology vaccine company, develops novel protein vaccines to prevent or treat bacterial infectious diseases. Its lead vaccine candidate is VAX-24, a 24-valent investigational pneumococcal conjugate vaccine for the prevention of invasive pneumococcal disease. The company also develops VAX-31 to protect against emerging strains and to help address antibiotic resistance; VAX-A1, a novel conjugate vaccine candidate to prevent disease caused by Group A Streptococcus; VAX-PG, a novel protein vaccine candidate targeting keystone pathogen responsible for periodontitis; and VAX-GI to prevent Shigella, a bacterial illness.